GlassScriptPhysician profile
Howard J Green
NPI 1245325380
$2,066.71
in general payments reported to CMS, 2019-2025
29 companies · $16.86 in 2025
The $16.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $137 · 2021: $262 · 2022: $351 · 2023: $546 · 2024: $349 · 2025: $16.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $374.26 | 2019-2022 | |
| Novo Nordisk INC | $314.47 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.26 | 2019-2024 | Jardiance, Synjardy |
| Stryker Corporation | $167.91 | 2024 | Everest Spinal System |
| Lilly USA, LLC | $127.32 | 2020-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $94.30 | 2020-2023 | |
| Abbvie INC. | $90.29 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $78.19 | 2019-2023 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $66.29 | 2019-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $63.83 | 2022-2024 | |
| Amgen INC. | $38.59 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $36.86 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $35.81 | 2023-2024 | Intellis Adaptivestim, Closurefast |
| Arcutis Biotherapeutics, INC. | $35.77 | 2024-2025 | Zoryve |
| Abbott Laboratories | $33.54 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $32.56 | 2022-2024 | Bd Onclarity |
| Leo Pharma INC. | $32.39 | 2019 | |
| Dexcom, INC. | $25.53 | 2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $21.22 | 2022 | |
| Amarin Pharma, INC. | $21.03 | 2020 | |
| Merck Sharp & Dohme LLC | $20.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.45 | 2022 | |
| Boston Scientific Corporation | $17.01 | 2023 | Exalt Model D |
| Masimo Corporation | $16.24 | 2023 | Set and Rainbow Set |
| Cranial Technologies, INC | $15.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2019 | |
| Hologic Sales and Service, LLC | $15.14 | 2019 | |
| Currax Pharmaceuticals LLC | $13.52 | 2021 | |
| Organogenesis INC. | $9.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.